Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordi Guardiola

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
International Journal of Cancer|February 11, 2017
The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patientsJoaquín Cubiella, Jayne Digby, Lorena Rodríguez-Alonso, et al.
Journal of Gastroenterology|October 11, 2016
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patientsMarisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, et al.
Cancers|February 11, 2023
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry StudyIvan Guerra, Luis Bujanda, Miriam Mañosa, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 14, 2025
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicityHugo Tejera-Pérez, Alejandro Velasco-Ruiz, María Chaparro, et al.
Inflammatory Bowel Diseases|March 3, 2016
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort StudyIván Guerra, Tamara Pérez-Jeldres, Marisa Iborra, et al.
Alimentary Pharmacology & Therapeutics|May 7, 2021
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term studyMaría José Casanova, María Chaparro, Óscar Nantes, et al.
Revista Espanola De Enfermedades Digestivas|September 29, 2025
Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remissionBeatriz Gros, Noemí Manceñido, José Manuel Benítez, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
International Journal of Cancer|February 11, 2017
The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patientsJoaquín Cubiella, Jayne Digby, Lorena Rodríguez-Alonso, et al.
Journal of Gastroenterology|October 11, 2016
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patientsMarisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, et al.
Cancers|February 11, 2023
Clinical Presentation, Management, and Evolution of Lymphomas in Patients with Inflammatory Bowel Disease: An ENEIDA Registry StudyIvan Guerra, Luis Bujanda, Miriam Mañosa, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 14, 2025
New insights into thiopurine toxicity: The contribution of rare XDH variants to myelotoxicityHugo Tejera-Pérez, Alejandro Velasco-Ruiz, María Chaparro, et al.
Inflammatory Bowel Diseases|March 3, 2016
Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort StudyIván Guerra, Tamara Pérez-Jeldres, Marisa Iborra, et al.
Alimentary Pharmacology & Therapeutics|May 7, 2021
Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term studyMaría José Casanova, María Chaparro, Óscar Nantes, et al.
Revista Espanola De Enfermedades Digestivas|September 29, 2025
Multicenter Spanish study on vedolizumab intravenous to subcutaneous switch in patients with inflammatory bowel disease in clinical remissionBeatriz Gros, Noemí Manceñido, José Manuel Benítez, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 10, 2022
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn's disease: Results from the ENEIDA registryMíriam Mañosa, Agnès Fernández-Clotet, Pilar Nos, et al.
Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.
Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.
Pageof 12